- BT CEO snaps up 400,000 shares
- GSK CEO offloads £2.3 million shares
- Poolbeg Pharma chairman ups his stake
Allison Kirkby CEO of BT (BT.A) has bought 400,000 shares at 107p for a total value of £428,000 on 20 February.
The move comes as the telecoms giant announced that it was offloading its iconic ‘BT Tower’ in London’s Fitzrovia to MCR for £275 million.
The company announced Kirkby’s appointment last July. Philip Jansen outgoing CEO left the telecoms giant in January this year.
Jansen had been in-post since 2019 and oversaw a period of change at BT, with the company’s share falling over 52% in the past five years.
Over the past year BT shares are down 23%.
GSK CEO SELLS OVER £2.3 MILLION SHARES
Emma Walmsley CEO of pharmaceutical giant GSK (GSK) has sold 139,792 shares at £16.58 for a total value of £2,317,709 on 19 February.
The sale was made to meet tax liabilities in relation to the vesting of shares granted in 2019 under the company's 2017 performance share plan.
Walmsley’s sale comes after the company delivered a strong set of results with total sales for 2023 rising 5% to reach £30.3 billion. Adjusting operating profit for 2023 was up 12% to £8.78 billion.
The pharmaceutical giant also recently announced promising results from the ‘LATITUDE’ phase three trial of its long-acting injectable HIV treatment Cabenuva.
GSK has a specialist HIV unit called ViiV Healthcare in partnership with Pfizer and Shionogi.
Over the past year GSK shares have gained 14% to sit at the £16 mark.
POOLBEG PHARMA DIRECTOR BUYS 830,000 SHARES
Cathal Friel chairman of Poolbeg Pharma (POLB) has bought 830,000 shares at 11.68p for a total value of £96,944 on 19 February.
Friel’s purchase shows ongoing commitment to the firm, he now holds 7.4% of the company’s issued capital.
Friel is also co-founder and chairman of infectious and respiratory diseases company hVIVO (HVO:AIM) and on 14 February he sold 25,937,909 shares at 28p for a total value of £7,262,615.
The sale was conducted as a secondary placing and included a sale of 4,017,270 shares by non-executive director Brendan Buckley at the same price.
Over the past year the shares have gained nearly 17%.
LEARN MORE ABOUT POOLBEG PHARMA
